Osteoporosis is a condition characterized by a reduction in the overall composition of bones throughout the body. It primarily manifests as a decrease in bone mass per unit volume within bone tissue. Bone minerals and bone matrix decrease proportionally with age (or after menopause in women), leading to changes in the microscopic structure of bone tissue and consequently altering its normal load-bearing function.Clinically, osteoporosis manifests as low back pain and pathological fractures. Vertebral deformities and postural changes leading to a "hunchback" appearance, accompanied by widespread skeletal pain, characterize the condition known as osteoporosis—a systemic skeletal disorder.
Classification of Osteoporosis:
Osteoporosis (sometimes simply referred to as bone loss) can be categorized as follows:
(1) Primary Osteoporosis: Such as senile osteoporosis and postmenopausal osteoporosis.
(2) Secondary Osteoporosis: Such as hyperthyroidism-related osteoporosis and diabetes-related osteoporosis.
(3) Idiopathic osteoporosis of unknown cause: such as hereditary osteoporosis.
Based on the extent of bone loss, it can be further divided into the following two categories:
(1) Generalized osteoporosis: such as senile osteoporosis, hyperthyroid osteoporosis, etc.
(2) Localized osteoporosis: Examples include rheumatoid arthritis-related osteoporosis and localized bone loss following prolonged limb immobilization in a cast.
Common therapeutic agents for osteoporosis:
1. Vitamin D preparations: As an essential nutrient and hormone, vitamin D plays a crucial role in maintaining calcium and phosphorus metabolism balance.
2. Calcitonin: Calcitonin therapy inhibits bone resorption and reduces bone loss.
3. Fluoride: Used for over 30 years to treat osteoporosis, fluoride promotes new bone formation. It significantly increases bone density and, under certain conditions, can restore bone density in osteoporosis patients to normal levels.
4. Estrogen: Estrogen supplementation in postmenopausal women markedly reduces fracture incidence.
5. Androgens: Androgenic agents stimulate bone formation.
6. Bisphosphonates: This class has become one of the primary drugs for preventing and treating various metabolic bone diseases characterized by osteoclast-mediated resorption, as well as high-turnover osteoporosis (predominantly resorption-driven).
7. Ipriflavone: As a synthetic isoflavone derivative, ipriflavone is clinically accepted due to its mild gastrointestinal side effects and excellent long-term tolerability and safety profile.
8. Vitamin K: Vitamin K primarily acts by increasing bone-specific protein (BGP) synthesis and secretion, functioning as an osteogenic promoter.
9.Parathyroid Hormone (PTH) Parathyroid hormone enhances osteoclasts' ability to resorb bone calcium and osteoclasts' function in absorbing bone matrix, while simultaneously promoting osteoblast formation and bone mineralization. This ensures continuous release of bone calcium to maintain serum calcium levels and enables constant replacement of old bone with new bone.Common calcium supplements include amino acid chelated calcium, calcium carbonate, calcium lactate, calcium citrate, and calcium gluconate. 11. Traditional Chinese Medicine (TCM) Extensive recent research and clinical application have confirmed that TCM formulas for tonifying the kidneys and strengthening bones yield satisfactory results in treating osteoporosis. These formulas exhibit minimal side effects, allow for long-term use, are moderately priced, and align well with China's national conditions.